International Biotechnology Trust’s Intellia Therapeutics NTLA Stock Holding History

International Biotechnology Trust’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$758K	Hold	24,000	–	–	0.26%	55
2023 Q2	$978K	Hold	24,000	–	–	0.3%	46
2023 Q1	$894K	Hold	24,000	–	–	0.25%	52
2022 Q4	$837K	Hold	24,000	–	–	0.26%	53
2022 Q3	$1.34M	Buy	24,000 +22,758	+1,832%	+$1.41M	0.43%	48
2022 Q2	$24K	Sell	1,242 -22,758	-95%	-$1.16M	0.25%	60
2022 Q1	$511K	Hold	24,000	–	–	0.12%	64
2021 Q4	$2.84M	Buy	+24,000	New	+$3.01M	0.63%	37

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

International Biotechnology Trust's NTLA Position: Q3 2023 in Review

International Biotechnology Trust held its Intellia Therapeutics (NTLA) position steady in Q3 2023 at 24,000 shares worth $758K. The position accounts for 0.26% of the portfolio, ranked #55.

International Biotechnology Trust first reported a position in NTLA in Q4 2021 and has held it in 8 quarters since. The position peaked at $2.84M in Q4 2021. 285 funds tracked by Wall St. Rank hold NTLA as of Q3 2023.

International Biotechnology Trust held 24,000 shares of Intellia Therapeutics worth $758K as of Q3 2023.
International Biotechnology Trust left its Intellia Therapeutics share count unchanged in Q3 2023.
Intellia Therapeutics made up 0.26% of International Biotechnology Trust's portfolio in Q3 2023, its #55 holding.
International Biotechnology Trust first reported a position in Intellia Therapeutics in Q4 2021 and has held it in 8 quarters since.
International Biotechnology Trust's Intellia Therapeutics position peaked at $2.84M in Q4 2021.
285 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.